Respiratory fluoroquinolone monotherapy for community-acquired pneumonia: a revised trial sequential analysis

Int J Antimicrob Agents. 2024 May;63(5):107153. doi: 10.1016/j.ijantimicag.2024.107153. Epub 2024 Mar 21.

Authors

Hsiu-Jung Lin¹, I-Wen Chen², Kuo-Mao Lan², Kuo-Chuan Hung³

Affiliations

¹ Department of Anesthesiology, E-Da Cancer Hospital, I-Shou University, Kaohsiung City, Taiwan.
² Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan City, Taiwan.
³ Department of Anesthesiology, Chi Mei Medical Center, Tainan City, Taiwan. Electronic address: ed102605@gmail.com.

PMID: 38521469
DOI: 10.1016/j.ijantimicag.2024.107153

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents* / therapeutic use
Community-Acquired Infections* / drug therapy
Community-Acquired Infections* / microbiology
Fluoroquinolones* / therapeutic use
Humans
Pneumonia / drug therapy
Pneumonia, Bacterial / drug therapy
Treatment Outcome

Substances

Fluoroquinolones
Anti-Bacterial Agents